Fig. 2From: Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in GermanyProgression-free survival relative to SHERBOC eligibility status. Kaplan–Meier curves for progression-free survival (PFS–1TL) in the therapy line before possible SHERBOC inclusion, relative to SHERBOC eligibility statusBack to article page